Jérôme Boursier

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu et al. · Hepatology · 2023 · 2.9K citations · Full text

Medicine, Internal Medicine, Pathology +17

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

Annalisa Berzigotti, Jérôme Boursier, Laurent Castéra et al. · Journal of Hepatology · 2021 · 1.8K citations · Full text

Medicine, Internal Medicine, Gastroenterology +16

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Jérôme Boursier, Olaf Mueller, Matthieu Barret et al. · Hepatology · 2015 · 1.5K citations

Life Sciences, Microbiology, Pathology +17

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12